for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CymaBay Therapeutics Inc

CBAY.OQ

Latest Trade

4.88USD

Change

0.00(0.00%)

Volume

8,660,161

Today's Range

4.02

 - 

5.36

52 Week Range

1.21

 - 

6.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.88
Open
4.36
Volume
8,660,161
3M AVG Volume
89.75
Today's High
5.36
Today's Low
4.02
52 Week High
6.55
52 Week Low
1.21
Shares Out (MIL)
68.88
Market Cap (MIL)
244.53
Forward P/E
-3.84
Dividend (Yield %)
--

Next Event

Cymabay Therapeutics Inc Annual Shareholders Meeting

Latest Developments

More

Cymabay Announces Positive Results From Enhance For Seladelpar In Patients With Primary Biliary Cholangitis

D. E. Shaw Reports 5% Passive Stake In Cymabay Therapeutics

CymaBay Reports First Quarter 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CymaBay Therapeutics Inc

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The PPARd receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar focuses on treating certain diseases of the liver and a variety of disorders of lipid metabolism.

Industry

Biotechnology & Drugs

Contact Info

7575 Gateway Blvd Ste 110

NEWARK, CA

94560-1194

United States

+1.510.2938800

http://www.cymabay.com/

Executive Leadership

Robert James Wills

Independent Chairman of the Board

Sujal A. Shah

President, Chief Executive Officer, Director

Charles A. McWherter

Senior Vice President, Chief Scientific Officer

Klara Dickinson

Chief Regulatory and Compliance Officer

Daniel Menold

Vice President - Finance

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.790

2018

-1.250

2019

-1.460

2020(E)

-0.925
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.40
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-42.54
Return on Equity (TTM)
-40.12

Latest News

Latest News

BRIEF-D. E. Shaw Reports 5% Passive Stake In Cymabay Therapeutics

* D. E. SHAW & CO., L.P. REPORTS 5% PASSIVE STAKE IN CYMABAY THERAPEUTICS AS OF MAY 26 -SEC FILING Source text: (https://bit.ly/3eUbW11) Further company coverage:

BRIEF-CymaBay Reports First Quarter 2020 Financial Results

* CYMABAY REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Engine Capital LP Deliveres Letter To Cymabay Therapeutics Nominating Arnaud Ajdler, Robert Frankfurt And Nadav Kidron To Board

* ENGINE CAPITAL LP SAYS ON MARCH 13, DELIVERED LETTER TO CYMABAY THERAPEUTICS NOMINATING ARNAUD AJDLER, ROBERT FRANKFURT AND NADAV KIDRON TO BOARD Source : (http://bit.ly/3aPfaRm) Further company coverage:

BRIEF-Engine Capital LP Deliveres Letter To Cymabay Therapeutics Nominating Arnaud Ajdler, Robert Frankfurt And Nadav Kidron To Board

* ENGINE CAPITAL LP SAYS ON MARCH 13, DELIVERED LETTER TO CYMABAY THERAPEUTICS NOMINATING ARNAUD AJDLER, ROBERT FRANKFURT AND NADAV KIDRON TO BOARD Source : (http://bit.ly/3aPfaRm) Further company coverage:

BRIEF-Cymabay Says Engine Capital Management Nominated 3 Candidates To Stand For Election To Board

* CYMABAY THERAPEUTICS COMMENTS ON ENGINE CAPITAL DIRECTOR NOMINATIONS

BRIEF-Cymabay Reports Q4 Loss Per Share $0.43

* CYMABAY REPORTS FOURTH QUARTER AND FISCAL YEAR END 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CymaBay Therapeutics scraps liver disease studies; shares plunge

CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage studies testing its experimental drug in patients with non-alcoholic steatohepatitis (NASH) and another liver disease after it observed "atypical" findings in one trial, sending shares down 76% in premarket...

BRIEF-CymaBay Therapeutics Q1 Loss Per Share $0.32

* CYMABAY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-CymaBay Initiates Phase 2B Study Of Seladelpar In Patients With Non-Alcoholic Steatohepatitis

* CYMABAY THERAPEUTICS ANNOUNCES THE INITIATION OF A PHASE 2B STUDY OF SELADELPAR IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS

BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis

* WEEK RESULTS FROM ITS ONGOING PHASE 2 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AT THE INTERNATIONAL LIVER CONGRESS™ 2018

BRIEF-Cymabay Reports Q4 Loss Per Share $0.11

* CYMABAY REPORTS FOURTH QUARTER AND FISCAL 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-CymaBay Announces Proposed Public Offering Of Common Stock

* CYMABAY THERAPEUTICS INC - ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING DEVELOPMENT OF SELADELPAR Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America

* CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics Says First Primary Biliary Cholangitis Patients Have Been Successfully Enrolled In Seladelpar Long-Term Extension Study

* CYMABAY THERAPEUTICS INC - FIRST PRIMARY BILIARY CHOLANGITIS PATIENTS HAVE BEEN SUCCESSFULLY ENROLLED IN SELADELPAR LONG-TERM EXTENSION STUDY Source text for Eikon: Further company coverage:

BRIEF-CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln

* CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2pRWkXa) Further company coverage:

BRIEF-CymaBay reports Q3 loss per share $0.21

* CymaBay reports third quarter 2017 financial results and corporate updates

BRIEF-Cymabay to deliver interim results from ongoing phase 2 study of Seladelpar at AASLD 2017

* Cymabay announces oral late-breaking presentation of interim results from an ongoing Phase 2 study of patients with primary biliary cholangitis at the AASLD 2017 Liver Meeting

BRIEF-CymaBay Therapeutics granted EMA orphan drug designation for seladelpar

* CymaBay Therapeutics granted EMA orphan drug designation for seladelpar for the treatment of primary biliary cholangitis Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics publishes Seladelpar proof-of-concept study

* Cymabay Therapeutics announces the publication of the Seladelpar proof-of-concept study for primary biliary cholangitis in lancet gastroenterology and hepatology

BRIEF-CymaBay Therapeutics reports Q2 loss per share $0.31

* CymaBay reports second quarter 2017 financial results and provides corporate update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up